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To say that the management of HIV infection in
prisons and jails is different than that in the free
world would be a great understatement.  The
challenges faced by correctional health care
providers in delivering high quality HIV care are
myriad and generally include the constraints
that accompany working within a system
designed primarily to meet security, rather than
medical needs.  Budgetary restraints, a patient
population that suffers disproportionately from
mental and physical co-morbidities and less-
than-ready access to subspecialty experts fur-
ther complicates care of these patients. 
What follows is a series of fictional clinical cases
that reflect familiar dilemmas correctional clini-
cians caring for HIV-infected patients encounter.
Each case is accompanied by a discussion of
potential options clinicians may consider.
Case 1. The Treatment-Experienced Patient
Entering Prison Off of Antiretroviral (ARV)
Therapy
Wayne R entered state prison after a three-
month stay at the county jail.  He first learned he
was HIV-infected four years prior, when incar-
cerated in another state facility, and was placed
on HIV therapy.  He cannot remember the
names of the medications he was previously
given, but believes some of them were "blue-
ish".  Between incarcerations he admits he was
intermittently adherent to his medication regi-
men, but rarely took any of his medications dur-
ing the past 12 months.
Upon entry to the county jail, Wayne R's CD4 T-
cell count was 387 cells/mm
3
and viral load was
76,800 copies/mL. He did not complain of
symptoms that could be ascribed to HIV infec-
tion and his weight increased during his incar-
ceration.  Upon entry to prison, basic HIV-relat-
ed laboratory tests were repeated.  At this time,
his CD4 T-cell count was 359 cells/mm
3
; viral
load was 94,900 copies/mL.  A genotype resis-
tance test was completed and demonstrated no
evidence of reduced susceptibility of the virus.
Jail medical records did not reveal Wayne R's
ARV treatment history.  A request for medical
information accompanied by a release of infor-
mation signed by the patient was sent to the
out-of-state prison and after six weeks of
repeated efforts, including a call to the facility,
records were obtained.  These records revealed
that the patient had a CD4 T-cell count of 223
cells/mm
3
when HIV was initially diagnosed and
had been given an ARV regimen containing
zidovudine/lamivudine (Combivir®) and nelfi-
navir.
Approximately three months after the patients'
arrival, his CD4 T-cell count was repeated and
was 312 cells/mm3.  At this time, the patient
complained only of increased fatigue.  His clini-
cian wanted to restart HIV therapy (and the
patient agreed) but the clinician was unsure
whether to reinitiate the medication regimen the
patient had previously been given or craft a new
combination using agents that are unlikely to be
affected by the resistance mutations the patient
may have cultivated, but were not detected on
resistance testing. 
Discussion: Correctional clinicians often find
themselves working in a "data vacuum".  Inmate
patients can be poor historians of their prior
medical care and requests for information from
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outside institutions, despite releases of
information, frequently go unheeded.  In
this case, records were procured, but only
after persistence by the medical staff.
Often, follow-up telephone calls to clinics
and hospitals have to be made to obtain
needed medical information.  Medication
data may also be obtained by contacting
community pharmacies the patient used
while not incarcerated.
In many cases, prior medication history is
simply not available.  Targeted questioning
of the patient may provide helpful clues as
to what medications the patient has taken
and which medications, due to resistance,
may be likely to be ineffective.  To deter-
mine if the patient ever took efavirenz, a
popular and potent non-nucleoside reverse
transcriptase inhibitor (NNRTI), which can
be rendered essentially ineffective with the
rapid development of few mutations, the
patient can be asked if he ever took gold-
colored medication at night that produced
vivid dreams.  Prior NNRTI experience in a
patient with poor adherence would raise
concern about NNRTI resistance.
Likewise, asking if a medication needed to
be refrigerated would help determine if
ritonavir or lopinavir/ritonavir (LPV/r)
(Kaletra®) were previously prescribed.
This patient recalled his pills were blue.  If
he also remembered that he needed to take
five pills twice a day and had some diarrhea
when on the medication, one could assume
he had received nelfinavir.  
In some cases, patients may recall nothing
about their medications.  In such situations,
starting a regimen that is most likely to be
effective despite prior treatment is prudent
when HIV therapy is indicated.  Ritonavir-
boosted protease inhibitors (PIs) may be
effective in this circumstance, as resistance
is unusual when such a combination is
used and there can be activity of the com-
bination even in the setting of prior pro-
tease inhibitor (PI) resistance.
After obtaining the patients' treatment histo-
ry, the clinician was confronted with the
choice of restarting the original regimen or
prescribing a new combination.  The
patients' intermittent adherence places him
at high risk for drug resistance.  This is dif-
ficult to document now that he has been off
therapy, as wild-type virus (not resistant)
will generally outgrow resistant virus once
the selective pressure of medication is
removed.  A notable exception is the per-
sistence of NNRTI resistance mutations
despite discontinuation of the NNRTI, yet
some assumptions can be made.  The first
mutation the patient may have acquired is
the M184V mutation, conferring high-level
resistance to lamivudine (3TC) and emtric-
itabine (FTC).  With on-going suboptimal
adherence to zidovudine (ZDV), thymidine
analogue mutations emerge.  Thymidine
analogue mutations lead to cross-resis-
tance to most of the nucleoside reverse
transcriptase inhibitors (NRTIs).  In the
worst-case scenario, mutations that reduce
susceptibility to inhibitors of the HIV-1 pro-
tease would have been selected.
Classically, nelfinavir resistance develops
with the D30N mutation, which leads to lim-
ited cross-resistance to other agents in this
(ARV) class but can be followed by more
damaging mutations that threaten the
effectiveness of this class of medications.  
At this time, determining which medications
this patient actually took is reduced to
guesswork.  Assuming the worst-case dual
ARV class resistance, the clinician would
be faced with the challenging task of
designing a salvage regimen.  There is little
attraction in restarting the original nelfi-
navir-based regimen, given it is relatively
inconvenient and demonstrated to be inferi-
or to more commonly used initial regimens.  
An alternative strategy would be to recom-
mend to the patient that he simply restart
Combivir
R
and nelfinavir temporarily for a
period of four weeks, at the end of which a
repeat in CD4 T-cell count and viral load
can be drawn along with a test of viral resis-
tance.  The goal here is to apply short-term
selective pressure with this regimen so that
resistant virus present in low concentra-
tions can outgrow wild type virus and
become readily detectable upon resistance
testing.  Four to six weeks of therapy with
this regimen should flush out resistant
strains, but be unlikely to lead to any further
resistance.  The resistance test results can
then be applied to direct decision-making.
For example, demonstration of only the
M184V mutation would be reassuring and
suggest a regimen containing ritonavir-
boosted PI plus tenofovir and ZDV would
likely be potent.  Some would also add FTC
or 3TC to preserve the M184V mutation, as
it has been associated with reduced ability
of the virus to replicate.
1
The presence of
NRTI mutations in addition, would indicate
a more novel approach is needed and the
combination of a ritonavir-boosted PI and a
NNRTI may be required.  Although such a
genotype might indicate that the virus
remains susceptible to both tenofovir and
didanosine, there is mounting evidence that
this pairing blunts CD4 T-cell count increas-
es and, when coupled with a NNRTI, leads
to suboptimal viral suppression.
2, 3
Much
less likely, but possible, would be the docu-
mentation of multi-class drug resistance
with thymidine analogue mutations, NNRTI
and multiple PI mutations.  In this situation,
aggressive multi-drug salvage therapy
including a boosted PI (i.e. lopinavir or
tipranavir) would be indicated to reverse
decreasing CD4 T-cell counts.  
When forced to make a decision with limit-
ed available data, the clinician can be
aggressive in obtaining outside records and
wisely apply understanding of the dynamics
of viral resistance to detect hidden muta-
tions before assuming the worst and
embarking on a new regimen that would
likely be costly and challenging for this
patient.  
Case  2. The HIV and Hepatitis B Virus
(HBV) Co-Infected Patient
Sylvia G was screened for HIV infection
soon after she arrived at prison.  She was
found to be HIV seropositive.  Follow-up
testing revealed a CD4 T-cell count of 567
cells/mm
3
and HIV viral load of 14,500
copies/mL.  Additionally, she had active
HBV infection evidenced by presence of
hepatitis B surface antigen (HBsAg).
Antibodies for hepatitis C virus (HCV) were
negative, hepatitis B e antigen (HBeAg)
was positive, HBV DNA PCR level was 6.8
x 108 IU/mL and ALT level was 2.8 times
the upper limit of normal.  The patient has
no evidence of cirrhosis on physical exam-
ination; albumin and synthetic liver function
parameters are within normal limits.  The
patient asks whether she needs to be treat-
ed for her HIV and HBV infections and, if
so, how?  She will be in prison for approxi-
mately 18 months.  
Discussion: HBV infection typically
receives less attention than HCV, particu-
larly in the setting of HIV co-infection.  The
lack of attention on this important pathogen
was reflected in a recent Wall Street
Journal editorial titled "Hepatitis B: The
Forgotten Virus".  Although less common
than HCV co-infection, the prevalence of
HBV infection is high among HIV-infected
persons (approximately 10%) as well as in
the general prison population (13%-47%).
4
Furthermore, HBV can be a significant
cause of liver disease in the setting of HIV
infection.  Screening of all HIV-infected indi-
viduals for active HBV infection is an impor-
tant aspect of HIV preventive care and can
be accomplished by testing for the pres-
ence of HBsAg.  
A remarkable boon to the therapeutic man-
agement of HIV/HBV co-infection is the
existence of agents that are active against
both viruses.  Tenofovir, 3TC and FTC all
have anti-viral activity against both HIV and
HBV.  Although none of these medications
are specifically approved by the Food and
Drug Administration (FDA) for the treatment
2
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of chronic HBV in the HIV-infected patient,
the dual activity of these antivirals has per-
mitted simultaneous treatment of both
viruses with standard HIV regimens (i.e.
3TC, FTC, efavirenz). Indeed, when ARV
therapy is indicated for HIV/HBV co-infect-
ed patients, inclusion of one or more drugs
active against HBV in the regimen is rec-
ommended.
5, 6
Some authorities recom-
mend that tenofovir be used preferentially,
in combination with FTC or 3TC, for
patients requiring treatment of both HIV
and HBV.
7
The use of tenofovir in such
patients has been advocated, despite the
black box label warning on this ARV that
states it is not indicated for the treatment of
chronic HBV and that acute exacerbations
of hepatitis can occur in individuals who
discontinue the drug. Similar warnings can
be found for other dually active NRTIs.
I
There is less clarity regarding the best
approach to take when there is no indica-
tion for the initiation of HIV therapy (i.e.
when CD4 T-cell count is high).  Use of
3TC, FTC or tenofovir alone, or when
paired, risks development of HIV resistance
to these agents, limiting their future use.  In
cases when CD4 T-cell count approximates
the HIV treatment threshold of 350
cells/mm
3
and/or when HIV viral load is
very high, some clinicians justify initiating a
regimen to treat both viruses.  Alternatively,
adefovir, a nucleotide analogue that is
FDA-approved for the treatment of HBV in
HIV-uninfected patients, can be dosed to
have activity against HBV and not HIV -
running no risk of incurring HIV drug resis-
tance.  Adefovir also has activity against
3TC-resistant HBV.
Another option was recently introduced
with the approval of entecavir
(Baraclude®), a nucleoside analogue that
is potent against HBV and has no antiviral
activity against HIV.  Entecavir was FDA-
approved this year for the treatment of HBV
mono-infection and for HIV/HBV co-infec-
tion in patients with prior 3TC experience.  
In this case, Sylvia G meets criteria for HBV
treatment.  She has active HBV as demon-
strated by HBV serologies and viral load,
as well as hepatic inflammation as evi-
denced by hypertransaminasemia; she has
no signs of cirrhosis on physical examina-
tion or laboratory testing.  It is difficult to
justify treatment for her HIV given her high
CD4 T-cell count and relatively low HIV viral
load.  Therefore, she should be treated with
an antiviral that has activity against HBV,
but that will not risk HIV ARV resistance.  At
present, adefovir is the best option. The
role of entecavir in such patients needs fur-
ther study.
Case  3. Acute HIV Infection 
Bruce S came to sick call asking to be test-
ed for HIV infection.  He states he was play-
ing basketball six weeks prior and during a
valiant attempt at rebounding, collided with
another inmate whose front teeth cut into
Bruce S's scalp.  According to the patient,
there was blood from the opposing player's
mouth and his own scalp following the col-
lision, but that this incident went unreport-
ed.  When he heard a rumor that the other
player is HIV positive, which the clinical
staff does not confirm to Bruce S but knows
to be the case, he asked to get tested for
HIV.  According to the medical record,
Bruce S had been HIV tested one year prior
upon prison entry and was seronegative.  
On examination, a linear puncture wound
was observed on the scalp with surround-
ing erythema and some pus evident.
Appropriate wound care and oral antibiotics
were administered.  Blood was drawn for
HIV antibodies, HIV viral load, HBV and
HCV serologies.  All test results were neg-
ative.  Approximately six weeks later, the
HIV antibody test was repeated.  This time
the test was positive and the confirmatory
Western blot indeterminate with three
bands reactive (p24, p40 and p55), sug-
gesting evolving HIV seroconversion.  The
surprised clinician ordered a follow-up viral
load, which returned at 350,000 copies/mL
and a subsequent genotypic resistance test
report demonstrated no viral resistance
mutations.  On further questioning, Bruce S
indicates that following the incident on the
basketball court he "may have" had unpro-
tected consensual sex with another inmate.  
The clinician caring for Bruce S is familiar
with the U.S. Department of Health and
Human Services (DHHS) guidelines on the
treatment of HIV-infected adults and ado-
lescents.
5
These guidelines describe the
potential risks and benefits of treatment
during acute HIV infection.  The clinician
telephones an HIV specialist at a nearby
academic hospital for advice regarding
whether to initiate ARVs.  The specialist
feels that treatment is likely to be beneficial
during acute infection but admits to only
seeing a handful of cases of acute HIV, all
of which have entered clinical studies.  
Discussion: Opportunities to detect acute
infection may be more abundant in correc-
tional settings where HIV transmission risk
behaviors are not rare and HIV testing is
usually accessible.  Yet, detection of acute
HIV infection requires consideration of the
diagnosis when presented with a patient
with a consistent history.  The diagnosis is
a challenge to make, as the presenting
symptoms of acute HIV infection are usual-
ly non-specific.  Fever, lymphadenopathy,
pharyngitis and/or rash are the most com-
mon findings on presentation.  In some
cases, encephalitis, rhabdomyolysis and
opportunistic infections may be seen; how-
ever, these are rare.  Given the nature of
the presenting symptoms, the clinician
must carefully probe for potential risky
exposures in the weeks prior when examin-
ing a patient with consistent symptoms,
much like we ask about tick exposures and
sick contacts in patients with febrile illness-
es.  
In this case, the patient presented with his
own concerns regarding a potential expo-
sure.  However, despite experiencing an
injury that could have led to HIV transmis-
sion, albeit a fairly low risk injury, laborato-
ry testing and detailed history-taking
revealed the patient did indeed recently
acquire HIV, though probably via a more
customary route than a defensive foul.  Had
he acquired HIV from the collision with the
HIV-infected basketball player, his HIV viral
load should have been detectable and high
over six weeks later when he first present-
ed.  Likewise, his HIV antibody tests would
have been expected to demonstrate at
least evolving seroconversion rather than
be completely negative.  
Converging data suggest that during the
acute phase of HIV infection, when the viral
load in the blood and genital secretions are
at their highest, the patient is most likely to
transmit virus to others.
8
Therefore, an
essential aspect of the management of
acute HIV infection includes counseling the
patient regarding risk behaviors as well as
contact tracing of recent sexual, needle
sharing and tattoo equipment sharing part-
ners.  
The clinicians' dilemma as to whether to
prescribe ARV therapy in this case is
shared by those working outside of prisons
and jails.  An aim of correctional health care
providers is to administer medical care that
is on par with the standard of care that
exists in the community.  However, the
community standard of care can some-
times be ill-defined, variable by community
or developing as new data emerge.  In the
case of acute HIV infection, treatment with
ARVs is common in some quarters, but at
present, cannot be considered standard
practice. The benefits of such early therapy
remain mostly theoretical and include
potential preservation of HIV-specific
immune function, possible lowering the
viral load set point and reduction in the
transmissibility of the virus.  Downsides
include exposure to treatment without pre-
viously proven clinical benefit, the potential
toxicity of therapy, the risk of drug resis-
tance and cost.  As stated in the DHHS
3
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guidelines, the clinician must consider the
evidence supporting early treatment and
the risks involved.  That the guidelines do
not definitively recommend ARV therapy
during acute infection does not mean it
should not be considered.  In fact, the
guidelines leave it as an option for the clin-
ician to consider. 
In this case, the clinician sought to learn the
community's practices regarding the man-
agement of acute HIV infection.  The clini-
cian has also read the relevant guidelines.
A discussion with the patient regarding the
risks, benefits and alternatives to ARV ther-
apy should follow.  Together, weighing the
available data, an educated decision can
be made.  If therapy is initiated, ARVs used
for patients with chronic HIV infection who
are initiating therapy can be employed.
Follow-up should include HIV viral load
testing and toxicity monitoring.  The optimal
duration of therapy following acute HIV
infection is not known.  Most clinicians dis-
continue HIV therapy initiated during acute
infection after six to 18 months.  Further
data regarding the optimal management of
acute HIV infection and the duration of HIV
treatment in this situation are expected to
emerge from on-going clinical studies.
Case 4. Multi-Drug Resistant (MDR) HIV 
Upon jail intake, Carrie R was very sick.
She had been abusing crack cocaine heav-
ily and had not been taking her ARVs or
Pneumocystis carni pneumonia (PCP) pro-
phylaxis as her health department physi-
cian's assistant (PA) had prescribed.
Within three days of her arrest, she was
transferred to the local hospital with fever
and shortness of breath.  PCP was diag-
nosed, CD4 T-cell count was 13 cells/mm
3
and an HIV viral load would eventually
return at 86,000 copies/mL.  After recover-
ing from PCP, the patient was transferred
back to the jail.  
Before hospital discharge the patient was
started on LPV/r and Combivir®, which she
had been on previously.  A genotypic resis-
tance test was performed and demonstrat-
ed multiple thymidine analogue mutations
including 41L, 118I, 210W, 215Y as well as
184V plus 103N (a class-killing NNRTI
DILEMMAS IN HIV CARE...
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IDCR Spotlight: Highlights of the 2005 Annual NCCHC Meeting 
Joseph Paris*, MD, PhD, Medical Director, Georgia Department of
Corrections
Courtney Colton* Managing Editor IDCR
*DISCLOSURES: Nothing to disclose
The 2005 annual Conference of the National Commission on
Correctional Health Care (NCCHC) took place on October 8-12,
2005 in Denver, Colorado.  This annual meeting is one of the most
important gatherings of correctional health care providers.  Prior to
the conference, IDCR hosted its' 9th annual pre-conference sym-
posium.  Despite competition from four other pre-conference sym-
posiums, there was standing room only throughout IDCR's ses-
sions. 
A short review of the IDCR symposium is presented here, for those
who were unable to attend.  
David Thomas, MD, JD (Professor and Chairman, Department of
Surgery, Division of Correctional Medicine, NovaSoutheastern
University) provided an overview on legal and ethical dilemmas
many correctional health care providers face when treating hepati-
tis C virus (HCV)-infected inmates.  Joseph Bick, MD (Director, HIV
Treatment Services, California Medical Facility, California
Department of Corrections) spoke on infection control within the
correctional setting, illuminating a number of barriers to cleanliness
that impact on the transmission of infections in prisons and jail.
Anne DeGroot, MD (Co-Chief Editor IDCR, Brown University) pro-
vided an update on HIV treatment recommendations for incarcerat-
ed women and presented on HCV for Bill Cassidy, MD (Associate
Professor of Medicine, Louisiana State University Health Sciences
Center), who was unable to attend the conference.  David Paar, MD
(Associate Professor of Medicine and Director of HIV Care for the
University of Texas Medical Branch at Galveston) concluded the
IDCR pre-conference seminar with a discussion on 2005 changes
to the HIV treatment guidelines.  
These issues are important to address because high-risk behaviors
prevalent among the incarcerated population combined with the lim-
ited access to health care prior to incarceration and poor health
care education, conspire to pose a formidable challenge to public
health. The correctional setting offers an unparalleled opportunity to
test, diagnose, educate and treat these patients.  The IDCR experts
focused on programs successfully integrated into the correctional
setting.  An enthusiastic audience peppered the experts with perti-
nent questions, and by the end, many stated that they wished there
had been even more time for questions.  After the seminar, every-
one had a chance to visit the new IDCR booth which drew a stream
of visitors throughout the NCCHC conference breaks.  
The conference continued with a well-attended Society of
Correctional Physicians (SCP) conference on Sunday, October 9
th
.
Death in restraints, mortality reviews, primary ENT and eye care
were topics presented by qualified speakers.  The SCP is a sister
organization of the IDCR and bundles IDCR publications into its
quarterly newsletter, CorrDocs.
The NCCHC opening ceremony on Monday, October 10
th
featured
a Keynote Address by IDCR board member, Louis Tripoli, MD, (Vice
President of Medical Affairs, CMS) who regaled the audience with
his touching adventures as a correctional physician in exotic loca-
tions including Fallujah, Abu Ghraib and other, equally dangerous
Iraqi locales.  The following three days were a whirlwind of concur-
rent breakout sessions in multiple tracks, including administration,
infectious disease, juvenile, legal, medical, mental health, nursing,
dental and professional development. 
IDCR board members also presented seminars during the confer-
ence proper.  David Paar, MD discussed methadone maintenance
and harm reduction in state and federal prisons.  Joseph Paris, MD,
PhD spoke on using ALT levels to determine HCV treatment eligi-
bility and Neil Fisher, MD (Medical Director, Chief Health Officer,
Martin Correctional Institute) gave a presentation on the rapidly
changing field of HIV medicine during one of the educational break-
fasts. Of note, Eric Avery, MD delivered a seminar regarding over-
coming mental health barriers in the treatment of HIV-infected incar-
cerated persons and John Maye, MD discussed prison health in
developing countries.  Drs. David Paar and David Thomas also
delivered lectures during the conference proper similar to those
which they presented during the IDCR pre-conference symposium. 
Continued on page 5
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mutation) and a series of PI mutations
including 10I, 30N, 36I, 74S and 90M that
suggest decreased response to most PIs.  
The patient has longstanding HIV infection
and was first treated with stavudine (d4T)
and 3TC.  Later she was treated with d4T,
3TC and nevirapine.  She also thinks she
may have been treated with a medicine that
can cause kidney-stones (i.e. indinavir) and
also nelfinavir, but is uncertain.   She rec-
ognizes the old formulation of didanosine
from a picture of the medication on a drug
company guide to ARVs.  She states she
was switched to LPV/r and Combivir®
approximately six months ago, upon return-
ing to a clinic after falling out of care.  
The PA discusses the results of the latest
genotype with the patient, who states this
episode of pneumonia was frightening and
that she never wants to go through another
bout of PCP again.  She is supposed to
remain in jail for approximately eight weeks
and will likely be transferred to the state
prison following her trial.
Discussion: Treatment of the patient with
MDR HIV infection is one of the most
daunting challenges confronting HIV health
care providers.  Often, as in this case,
resistance has been cultivated during
repeated bouts of non-adherence - often
fueled by substance abuse, mental illness
and other causes of personal chaos.  When
faced with a genotype report that has more
red ink than black, the clinician and patient
must have a frank discussion about what
the patient feels she is capable of and will-
ing to do to forestall HIV progression.
Incarceration may be an optimal time to
engage in such a discussion as the patient
will be free from substance abuse, may be
getting appropriate treatment of underlying
depression or other mental illness and can
be monitored closely.  
The aims of therapy must be made clear.
Attempting to suppress the HIV viral load to
undetectable levels may no longer be a
realistic goal.  Instead, therapy that can
impede the virus in its CD4 T-cell count
destruction should be employed to slow
disease progression and stall for time as
newer therapies are developed.
Therapeutic management of multi-drug
resistance involves two complimentary
approaches: application of new agents that
are likely to have antiviral activity against
the virus and use of drugs to which the
virus is resistant, but that reduces the abili-
ty of the virus to replicate. 
Enfurvitide (T-20) and tipranavir are newer
agents that are almost exclusively pre-
scribed as part of "salvage" regimens.  T-20
is an injectable HIV entry inhibitor.  Its use
in jails and prisons can be problematic,
given it requires injection and is expensive,
even by HIV treatment standards.
Tipranavir is a PI that has been found to be
more effective among patients with MDR
HIV infection than optimized background
therapy.
9
These data demonstrate that
tipranavir is most effective when combined
with T-20 in patients who have not previ-
ously taken T-20.  Tipranavir requires
boosting with 400 mg of ritonavir daily.
Abbott Laboratories supplies this dose of
ritonavir for use with tipranavir at no cost.  A
series of mutations have been described
that reduce the activity of tipranavir.
Guidelines on the use of tipranavir have
been drafted by the American Academy of
HIV Medicine (AAHIVM).
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In addition to the initiation of novel thera-
pies, recycled ARVs or continuation of
drugs to which the virus is resistant, are
often included in salvage regimens.  Some
mutations, particularly against NRTIs,
appear to reduce viral fitness and may pro-
vide clinical benefit when maintained.
Examples of this effect have been
described with 3TC and NRTIs.
1
The oper-
ative theory here is that highly mutated
virus is defective, less able to replicate and
less able to deplete CD4 T-cells.  There has
been no significant effect of maintaining
NNRTIs when resistance to this class of
ARVs is present.  
In this case, the PA and the patient dis-
cussed the need for aggressive HIV thera-
py.  The patient again stated her commit-
ment to "whatever it takes" to get well.  After
consultation with an HIV specialist and the
medical director of the jail, the PA pre-
scribed tipranavir/ritonavir, T-20, tenofovir,
FTC and ZDV - an aggressive and expen-
sive option that may not be available in
many jails.  
Conclusion 
Correctional clinicians have unique institu-
tional barriers when interacting with their
patients.  However, these clinicians also
have unique opportunities; the cluster of
individuals with a history of high-risk behav-
iors is an opportunity for both clinical and
behavioral intervention.  The cases studies
above can also include the opportunity to
provide education regarding: 1) basic dis-
ease/infection information; 2) the impor-
tance of treatment adherence, including
access to treatment upon release; 3) fur-
ther education and support for disclosure to
previous partners for follow-up counseling
and testing, if and when appropriate and, at
every opportunity; 4) behavioral risk/harm
reduction.
DILEMMAS IN HIV CARE...
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Dear Correctional Colleagues:
This month, IDCR focuses on common dilemmas in the care of the HIV-infected incarcerated indi-
vidual.  Dr. David Wohl reviews four common scenarios faced by HIV-infected inmate patients and
their clinicians: the treatment-experienced patient entering prison off of antiretroviral therapy, the
HIV and hepatitis B virus co-infected patient, acute HIV infection and multi-drug resistant HIV.  
Dr. Wohl points out that these common dilemmas are made more challenging given the constraints
that exist in jails and prisons.  Correctional clinicians must often seek creative solutions to meet the
needs of their incarcerated patients. We believe that IDCR continues to serve an important role in
disseminating these "best practice" solutions to our colleagues who work behind bars.
Also in this issue, Dr. Joseph Paris and IDCR managing editor Courtney Colton review the high-
lights of this autumn's annual Conference of the National Commission on Correctional Health Care,
which took place in October in Denver, Colorado.  This annual meeting is one of the most impor-
tant gatherings of correctional health care providers.  
This month's HIV101 provides a table of currently available antiretroviral (ARV) agents, with com-
ments on the advantages and disadvantages of each ARV class.
At the end of this issue, readers should be familiar with some of the dilemmas faced in correction-
al healthcare and how to best tackle these dilemmas.  Readers should also be familiar with pre-
ferred and alternative regimens for the initial treatment of HIV.
I would like to take this opportunity to extend our gratitude to Dr. David Thomas, who has served
this past year as IDCR's Co-Chief Editor. We appreciate Dr. Thomas' long-term commitment to the
health of the incarcerated, and thank him for the fine job that he has done for IDCR this past year.
Dr. Wohl, an active member of IDCR's Editorial Board, has agreed to step up and manage content
for 2006.  Dr. Wohl is an Associate Professor of Medicine, Division of Infectious Diseases,
University of North Carolina, and is Co-Director of HIV Services for the North Carolina Department
of Corrections.  We all look forward to working with Dr. Wohl during this coming year to ensure that
IDCR continues to meet the educational needs of our correctional colleagues around the world. 
Sincerely,
Joseph Bick*
*Nothing to Disclose
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# pills/day
HIV101: INITIAL TREATMENT: PREFERRED REGIMENS
Efavirenz* 
+ (lamivudine [3TC] or emtricitabine [FTC])
+ (zidovudine [AZT, ZDF] or tenofovir DF [TDF])
2-3
# pills/day
Lopinavir/ritonavir (Kaletra®) 
+ (lamivudine [3TC] or emtricitabine [FTC])
+ (zidovudine [AZT, ZDF])
8-9
NNRTI-Based PI-Based
# pills/day
Efavirenz* 
+ (lamivudine [3TC] or emtricitabine [FTC])
+ (abacavir [ABC] or didanosine [ddI] or 
stavudine [d4T]) 
Nevirapine** 
+ (lamivudine [3TC] or emtricitabine [FTC])
+ (zidovudine [ZDV] or stavudine [d4T] or didano-
sine [ddI] or abacavir [ABC] or tenofovir [TDF])
2-4
NNRTI-Based
HIV101: INITIAL TREATMENT: ALTERNATIVE REGIMENS
3-6
# pills/day
Atazanavir 
+ (lamivudine [3TC] or emtricitabine [FTC])
+ (zidovudine [ZDV] or stavudine [d4T] or aba-
cavir [ABC] or didanosine [ddI]) or (tenofovir
[TDF] + ritonavir [RTV] 100mg/d)
Lopinavir/ritonavir (Kaletra) 
+ (lamivudine [3TC] or emtricitabine [FTC])
+ (stavudine [d4T] or abacavir [ABC] or tenofovir
[TDF] or didanosine [ddI])
Fosamprenavir or fosamprenavir/ritonavir or indi-
navir/ritonavir or nelfinavir or saquinavir (hard- or
soft-gel capsule)/ritonavir
+ (lamivudine [3TC] or emtricitabine [FTC])
+ (zidovudine [ZDV] or stavudine [d4T] or aba-
cavir [ABC] or tenofovir [TDF] or didanosine
[ddI])
3-6
PI-Based
7-10
5-15
# pills/day
Abacavir [ABC] + lamivudine [3TC] + zidovudine
[ZDV]^
2
NRTI-Based
*Avoid in pregnant women and women with high pregnancy potential.
**Because of higher rates of hepatotoxicity, nevirapine should not be initiated in women with pre-nevirapine CD4-T cell counts
less than 250 cells/mm3 or men with CD4-T cell counts less than 400 cells/mm
3
, unless the benefit clearly outweighs the risk.
^To be used only when a preferred or alternative NNRTI- or PI-based regimen cannot or should not be used as first-line theapy.
Tables adapted from DHHS.  Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.  October 6,
2005.  Last accessed November 16, 2005 from  http://aidsinfo.nih.gov/guidelines/default_db2.asp?id=50
There is a New Form of Kaletra
How Kaletra looks will change and so will the number of pills.
If you were taking 6 red-orange capsules each day you will now take 4 gold
tablets each day.
OLD
Red-Orange
Capsules
NEW
Gold
Tablets
13th Annual Conference
on Retroviruses and
Opportunistic Infections
February 5-9, 2006
Denver, Colorado
Visit:  
www.retroconference.org
13th Annual Ryan White
National Youth
Conference on HIV/AIDS
February 18-20, 2006
Philadelphia, PA
Visit:
www.napwa.org/rwnyc/
National Conference on
African-Americans and
AIDS
February 27-28, 2006
Philadelphia, PA
Visit:  
www.minority-health
care.com/
Updates in Correctional
Health Care
April 8-11, 2006
Las Vegas, Nevada
www.ncchc.org
ACHSA 2006
Multidisciplinary Training
Conference
May 11-13, 2006
Durham, North Carolina
http://achsa.org
XVI International AIDS
Conference 
August 13-18, 2006
Toronto, Canada 
Visit: www.aids2006.org
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Resistance Testing for Naïves is Cost-Effective
Utilizing a previously published model of HIV dis-
ease, Sax, et al, projected the long-term and clinical
cost outcomes for a cohort of HIV-infected, antiretro-
viral (ARV)-naïve patients who undergo pretreatment
resistance testing.  In the base case, the overall
prevalence of ARV resistance among treatment-
naïve patients was 8.3%.  Direct costs of treatment
for both routine medical care and for acute illnesses
were estimated from data from the AIDS Cost and
Services Utilization Survey.  In the absence of prima-
ry resistance testing, patients had a projected mean
quality-adjusted life expectancy of 168.3 months and
a total lifetime cost of $336,000.  With resistance test-
ing at the time of initial diagnosis, the mean quality-
adjusted life expectancy increased to 169.3 months
and total costs increased to $338,600.  Study authors
concluded that resistance testing at the time of HIV
diagnosis is a cost-effective strategy that can lead to
selection of a more effective initial ARV regimen and
likely longer survival for patients who have drug-
resistant virus.
Sax P, et al.  Should resistance testing be performed
for treatment-naïve HIV-infected patients: a cost-
effectiveness analysis.  Clin Infect Dis.  2005;
41(9):1316-23.
HPV Vaccine in Phase III Clinical Trials
GARDASILTM, a quadrivalent human papillomavirus
virus (HPV) type 6, 11, 16, 18 recombinant vaccine,
has been evaluated in a Phase III study, titled
FUTURE II. Over 12,000 women, aged 16 to 26
years, at 90 centers  were randomized to receive a
three-dose regimen of either GARDASIL or placebo
at day 1, month 2 and month 6.  Among women who
received three doses of GARDASIL, 100% of high-
grade cervical pre-cancers and non-invasive cervical
cancers (CIN 2/3 and AIS) associated with HPV
types 16 and 18 were prevented.  Twenty-one cases
of CIN 2/3 or AIS were observed in the placebo
group.  This trial is part of the ongoing phase III pro-
gram for GARDASIL, which involves over 25,000
people in 33 countries worldwide.
Finn S, et al.  Prophylatic quadrivalent human papil-
lomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like
particle (VLP) vaccine (GardasilTM) reduces cervical
intraepithelial neoplasia (CIN) 2/3 risk.  Oral abstract
LB-8a.  Infectious Diseases Society of America meet-
ing.  San Francisco, CA.  October 7, 2005.
A New Way to Prevent HIV?
Vaginal microbicides, chemical substances that,
when applied to the vagina before heterosexual inter-
course, have the potential to prevent or reduce HIV
transmission.  The non-nucleoside reverse transcrip-
tase inhibitor, TMC120, is one such HIV microbicide
candidate currently being tested in Phase I clinical
trials.  In a recent study, Malcolm, et al measured the
daily amounts of TMC120 released from silicone
elastomer vaginal rings over a 71-day period.  An
average TMC120 daily release of 136 µg/day was
determined by linear regression.  Based on upper
limits for the volumes of cervicovaginal fluid and
semen, and assuming that the in vivo and in vitro
release rates of TMC120 are similar, then the con-
centrations of TMC120 in the combined fluids are cal-
culated to be within the range required to prevent HIV
infection (.01 µM at 10 min, 1.1 µM at 1 hr, 13.2 µM
at 12 hr).  Study authors concluded that there is the
potential for providing protection against HIV infec-
tion in the form of a female-controlled vaginal ring
device.
Malcolm R, et al.  Long-term, controlled release of
the HIV microbicide TMC120 from silicone elastomer
vaginal rings.  Jour Antimicrobial Chemo.  2005;
56(5):954-6.
HIV/HCV Co-infected Liver Transplant Candidates
Liver disease is the leading cause of death for
HIV/HCV co-infected patients.  Despite equivalent
Model for End-Stage Liver Disease (MELD) scores at
the time of liver transplantation listing, HIV-infected
patients demonstrate significantly shorter pre-trans-
plantation survival time when compared with non-
HIV-infected patients.  Shorter pre-transplantation
survival times among these patients are primarily
associated with death related to infection.  To
improve the survival of the HIV/HCV co-infected liver
transplant candidate, Stock recommends early refer-
ral of the co-infected patient for liver transplantation.
Co-infected patients must meet the same standards
as all liver transplant recipients, including a pro-
longed period of abstinence from alcohol and nar-
cotics, sufficient rehabilitation and demonstration of
social support.  Additionally, co-infected liver trans-
plant candidates must have CD4-T cell counts
greater than 100, the absence of current opportunis-
tic infections and documentation that HIV can be sup-
pressed with an antiretroviral regimen.  In the early
experience of solid organ transplantation among HIV-
infected patients, most transplant centers still deter-
mine transplant eligibility according to MELD scores.
Unfortunately, by the time liver function deteriorates
to a point where the MELD score is sufficiently high
for transplant eligibility, HIV-infected candidates no
longer meet the entry criteria applied by most trans-
plant centers.  Synchronized multi-special care com-
bined with early referral will help to minimize the
number of deaths among co-infected patients on liver
transplant waiting lists.
Stock G.  Rapid deterioration of HIV co-infected
patients waiting for liver transplantation is not pre-
dicted by MELD.  Liver Transplantation.  2005;
11(11):1315-17.
Organ Transplants for HIV Patients
AB228, authored by Assemblyman Paul Koretz and
recently signed by California Governor Arnold
Schwartzenegger, is the first bill passed by the
California State Legislature that prohibits health
insurers from denying coverage for organ transplants
based solely on a patients' HIV status.  Historically,
HIV-infected patients have not been considered suit-
able candidates for organ transplantation due to their
relatively shortened lifespan.  However, antiretroviral
therapy has greatly extended the life expectancy of
these patients and studies have shown that organ
transplants in qualified HIV-infected patients lead to
similar outcomes when compared to non-HIV-infect-
ed patients.
California Political Desk.  American Chronicle.
September 29, 2005. Last accessed October 26,
2005 articleID=2665
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SELF-ASSESSMENT TEST FOR CONTINUING MEDICAL EDUCATION CREDIT
Brown Medical School designates this educational activity for one hour in category one credit toward the AMA Physician’s Recognition
Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through February 28, 2006. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1.  The following is not a preferred ART regimen for ART-naïve
patients:
A. Efavirenz plus 3TC
B. Efavirenz plus TDF
C. Kaletra® plus TDF
D. Kaletra® plus 3TC
E. None of the above
2.  The following medications have anti-viral activity against both
HIV and HBV:
A. Tenofovir
B. 3TC
C. TDF
D. A and B
E. A and C
3.  Entecavir has antiviral activity against both HIV and HBV.
True or False?
A. True
B. False
4. Which of the following mutations is paired correctly with the
respective antiviral to which it confers resistance?
A. D30N; nelfinavir 
B. M184V; FTC
C. D30N; 3TC
D. M184V; nelfinavir
E. A and B
F. C and D
5.  Patients are most likely to transmit HIV during the acute
stages of HIV infection.  True or False?
A. True
B. False
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IDCR EVALUATION
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
In the News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that IDCR helps you in your work?
Why or why not?
3. What future topics should IDCR address?
4. How can IDCR be made more useful to you?
5. Do you have specific comments on this issue?
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